Novavax Inc. ($NVAX) Stock Forecast: Up 6.3% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company focused on the development of vaccines for infectious diseases. Today, the stock experienced a strong bullish movement in the market.

Why is Novavax Inc. going up?

NVAX stock is up 6.3% on May 26, 2026 14:15

• Novavax Inc. (NVAX) stock outperformed its competitors and major indices like the NASDAQ Composite and Dow Jones Industrial Average, showcasing resilience and strength in its market position.
• The fluctuation in Novavax's stock price can be attributed to its operating margin percentage, indicating potential financial health and operational efficiency improvements.
• Despite a recent decline, Novavax bounced back with a 4.16% increase, breaking a losing streak and demonstrating investor confidence in the company's future prospects.
• Overall, Novavax's stock movement today reflects both internal financial metrics and broader market trends, positioning the company as a key player in the biotechnology sector with promising growth potential.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Operating margin % of Novavax, Inc. – BSESOF:NVV1

This article provides financial data for Novavax, Inc. (BSESOF:NVV1), specifically focusing on its operating margin percentage. It highlights that the market for NVV1 is currently closed with no trades. The article also mentions the sources for its market and reference data, including ICE Data Services and FactSet.

https://www.tradingview.com/symbols/BSESOF-NVV1/financials-statistics-and-ratios/operating-margin/

Novavax Inc. stock outperforms competitors on strong trading day

Novavax Inc. (NVAX) stock advanced by 2.56% to $9.21 on a strong trading day, outperforming the NASDAQ Composite Index and the Dow Jones Industrial Average. The company's stock closed 23.06% below its 52-week high of $11.97, achieved on February 26th. This performance occurred during a favorable market session where major indices also saw gains.

https://www.marketwatch.com/data-news/novavax-inc-stock-outperforms-competitors-on-strong-trading-day-cb3dfff1-19b0b45cbfba

Novavax Inc. stock underperforms Thursday when compared to competitors

Novavax Inc. (NVAX) stock fell by 3.13% on Thursday, closing at $8.98, despite an overall positive trading day for the broader market indices like the NASDAQ Composite and Dow Jones Industrial Average. The company's shares are currently trading 24.98% below their 52-week high of $11.97, which was reached on February 26th.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-thursday-when-compared-to-competitors-5234ae4b-f4cf7a230ea3?mod=mw_quote_news

Novavax Inc. stock outperforms competitors on strong trading day

Novavax Inc. (NVAX) saw its stock increase by 4.16% to $9.27, outperforming major indices like the NASDAQ Composite and the Dow Jones Industrial Average. This rise broke a three-day losing streak for the company. The positive trading session saw the NASDAQ Composite rise 1.54% and the Dow Jones Industrial Average increase by 1.31%.

https://www.marketwatch.com/data-news/novavax-inc-stock-outperforms-competitors-on-strong-trading-day-25339edd-939ac012f093?mod=mw_quote_news

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Down 5.3% Today

Gasoline ($GASOLINE) Commodity Forecast: Down 5.1% Today

Natural Gas ($GAS) Commodity Forecast: Up 2.9% Today

Affirm Holdings Inc. ($AFRM) Stock Forecast: Up 5.0% Today

Teradyne, Inc. ($TER) Stock Forecast: Up 5.2% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.1% Today

Ambarella Inc. ($AMBA) Stock Forecast: Up 5.2% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Down 7.2% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.7% Today

Circle Internet Group ($CRCL) Stock Forecast: Down 5.5% Today

Novavax Inc. Price History

07.04.2026 - NVAX Stock was down 7.6%

• Despite a decline in revenue and a shift to a net loss in Q1 2026, Novavax's stock surged by 17.4%. Investors seemed to focus on the company's new partnership approach and future potential earnings rather than its financial results.
• Novavax initially saw its stock rise due to strong first-quarter financial results, which surpassed sales expectations and emphasized strategic collaborations. Nevertheless, the market sentiment shifted, resulting in the recent bearish trend.
• Novavax's stock had been performing well in recent trading sessions, outpacing competitors and benefiting from a favorable market environment. Profit-taking activities today likely triggered the observed bearish movement.

07.04.2026 - NVAX Stock was up 4.1%

• Despite facing a significant revenue drop and transitioning to a net loss in Q1 2026, Novavax saw a 17.4% increase in its stock value, indicating investor confidence in its shift to an asset-light, partnership-focused business strategy.
• The company's Q1 financial performance surpassed expectations, surpassing sales forecasts and demonstrating a strengthened financial position through new credit facilities and key partnerships, driving the positive movement in Novavax's stock.
• Novavax reiteration of its 2026 sales outlook, combined with optimistic technical analysis signaling a decrease in downward pressure, further bolstered investor confidence, contributing to the stock's robust performance.
• Novavax's strong stock performance was also evidenced by its outperformance relative to competitors on a flourishing trading day, during which both the NASDAQ Composite and Dow Jones Industrial Average experienced significant gains.

26.04.2026 - NVAX Stock was up 6.3%

• Novavax Inc. (NVAX) stock outperformed its competitors and major indices like the NASDAQ Composite and Dow Jones Industrial Average, showcasing resilience and strength in its market position.
• The fluctuation in Novavax's stock price can be attributed to its operating margin percentage, indicating potential financial health and operational efficiency improvements.
• Despite a recent decline, Novavax bounced back with a 4.16% increase, breaking a losing streak and demonstrating investor confidence in the company's future prospects.
• Overall, Novavax's stock movement today reflects both internal financial metrics and broader market trends, positioning the company as a key player in the biotechnology sector with promising growth potential.

13.04.2026 - NVAX Stock was down 5.2%

• Following positive updates like collaborations with Pfizer and Sanofi, Novavax (NVAX) saw a rise in stock value but observed a downward trend in the current trading session.
• The company's weaker market performance compared to its competitors hints at a potential shift in investor sentiment, leading to profit-taking activities or concerns about its future growth.
• Mixed signals from technical indicators signaling a strong buy stance while options data suggests a preference for downside protection, indicating uncertainty surrounding NVAX's future direction.
• Despite recent positive developments propelling Novavax forward as a growth-oriented player in the vaccine industry, persistent challenges related to profitability and debt likely contributed to today's negative market movement.

06.04.2026 - NVAX Stock was up 14.4%

• Novavax (NVAX) stock exhibited robust bullish growth, surpassing industry peers and the general market.
• Despite predictions of a notable decline in year-on-year revenue, Novavax's stock price surged, potentially influenced by positive outlook or expectations regarding the upcoming earnings.
• The investment stake by Vanguard Capital Management, a significant yet passive investor, could have also played a role in the favorable market dynamics.
• Observers are eagerly anticipating Novavax's financial results for the first quarter of 2026, with the impending disclosure likely fueling the current positive momentum in the stock price.

06.04.2026 - NVAX Stock was up 19.1%

• Novavax reported first-quarter revenue of $139.5 million, surpassing estimates by a significant margin, showcasing strong financial performance.
• The company's revenue was driven by milestone payments from vaccine supply and licensing deals, offsetting declining demand for its COVID-19 vaccine.
• Novavax's strategy of licensing its vaccine technology to other pharmaceutical companies has helped insulate it from uncertainties and cut costs, contributing to its positive earnings report.
• Despite facing pressure from activist investors and missing revenue forecasts in the past, Novavax's stock outperformed competitors on the back of its strong financial results, indicating investor confidence in the company's future prospects.

20.04.2026 - NVAX Stock was up 5.3%

• NVAX stock has recently lagged behind its competitors, but today's positive movement suggests a potential shift in investor sentiment.
• Analysis indicates a temporary negative sentiment with a positive long-term projection, signaling investors' focus on broader factors beyond short-term fluctuations.
• Novavax's emphasis on entering seasonal booster markets and expanding its vaccine offerings may contribute to the optimistic investor sentiment and the stock's recent upswing.
• Updates on Novavax's advancements in COVID-19 vaccine development and strategic initiatives post-pandemic are likely factors driving confidence in the company's future, reflected in today's positive market performance.

08.04.2026 - NVAX Stock was up 8.8%

• NVAX's stock exhibited strong bullish movement recently.
• The filing of a Form 144 Notice of Proposed Sale of Securities introduced some initial uncertainty but was later overshadowed by positive developments.
• NVAX's participation in the BofA Securities 2026 Health Care Conference was met with investor interest and confidence in the company's future.
• A surprising Q1 revenue beat was attributed to a significant deal with Pfizer and a shift towards a licensing model, illustrating NVAX's agility and innovation in a competitive market, leading to the positive movement in its stock price.

11.04.2026 - NVAX Stock was down 8.4%

• Novavax has shown positive developments lately, including strong Q1 earnings and partnerships with Pfizer and Sanofi; however, the stock trended bearishly today.
• Investor concerns may have arisen due to the filing of a Form 144 Notice of Proposed Sale of Securities, potentially leading to selling pressure on the stock.
• Participation in the upcoming BofA Securities 2026 Health Care Conference could offer Novavax a platform to address investor uncertainties and restore market confidence.
• Differing opinions from technical indicators signaling a strong buy and options data pointing to downside protection by the "smart money" likely contributed to the bearish sentiment surrounding the stock.

11.04.2026 - NVAX Stock was down 5.6%

• Today, NVAX stock experienced marked bearish activity attributed to profit-taking by investors following a recent strong rally.
• Positive developments, such as a robust Q1 earnings performance, a significant deal with Pfizer, and an expanded partnership with Sanofi, were overshadowed by concerns regarding negative equity and cash depletion, impacting investor confidence.
• The disclosed insider plan to sell securities, according to an SEC filing, likely contributed to the stock's decline.
• NVAX's comparative underperformance against industry peers amid a broader market downturn indicates the potential impact of general market conditions on today's bearish trend.

08.04.2026 - NVAX Stock was up 13.4%

• Novavax's stock experienced a strong bullish movement of 13.98% following a robust Q1 earnings report and positive developments in its COVID-19 vaccine technology, driven by the following factors:
• The announcement of a licensing deal with Pfizer for its Matrix-M adjuvant technology and an expanded partnership with Sanofi boosted investor confidence in the company's future growth potential.
• The unexpected revenue beat in Q1, amounting to $139.5 million, surpassed analysts' expectations and showcased Novavax's ability to pivot towards a licensing model, reducing its reliance on direct vaccine sales.
• Participation in the BofA Securities 2026 Health Care Conference further highlighted Novavax's strategic positioning and potential for future collaborations and advancements in the healthcare industry.
• Despite a slight underperformance compared to competitors on a previous trading day, the overall positive sentiment surrounding Novavax's recent developments and financial outlook contributed to the bullish market movement.

14.04.2026 - NVAX Stock was down 5.0%

• NVAX stock closed at $9.23, showing a bearish movement of 4.05% today.
• Despite recent positive news related to partnerships and earnings, NVAX underperformed its competitors and the broader market.
• The mixed trading session and market sentiment likely played a role in the bearish movement of NVAX stock.
• Investors, especially the "smart money," exhibit caution towards the stock's long-term prospects. Technical indicators lean towards a strong buy, while options data signal a preference for downside protection.